Research Reports


Home » Reports » Global Diabetic Retinopathy Drug Market Analysis Opportunity Outlook 2021
Market Research Report

Global Diabetic Retinopathy Drug Market Analysis & Opportunity Outlook 2021

Published On : December, 2018 REP-ID-99 Category: Healthcare

Diabetic retinopathy is a medical condition which damages retina (present at the back of eye) and leads to blindness if untreated or undiagnosed. The degree of treatment of diabetic retinopathy varies according to various stages of the disease and is mainly prioritized to curb the disease at its initial stage.

The global diabetic retinopathy drug market is anticipated to bolster at a robust growth rate to reach USD 705 Million by 2021. Geographically, the global diabetic retinopathy drug market is segmented into North America, Latin America, Western and Eastern Europe, Asia-Pacific, Middle East and North Africa (MENA) and Rest of World.

Market Segmentation

  • By Type of Drugs

The global diabetic retinopathy drugs market is segmented based on type of drugs into intraocular steroid injection, Avastin, Lucentis and Anti-Vascular Endothelial Growth Factor (VEGF) drug.

  • By End Users

On the basis of end-users, the global diabetic retinopathy drug market is divided as ophthalmic clinics, hospitals, ambulatory surgical centers and others.

Growth Drivers and challenges

Rapidly expanding diabetic population coupled with increasing awareness of people regarding diabetic retinopathy is expected to drive the growth of global diabetic retinopathy drug market in coming 4-5 years. In addition to that, rising medical procedures due to high penetration of medical insurance and rising government initiatives for prevention of diabetes related risks is also believed to garner the growth of global retinopathy drug market in future.

However, lack of trained ophthalmologist and stringent government regulations for approval of diabetic retinopathy drugs is anticipated to restrain the growth of global diabetic retinopathy drugs market over the forecast period i.e. 2015-2021.        

Market Size and Forecast

Regionally, North America dominates the global diabetic retinopathy drug market. The region also accounted for 36.0% of total diabetic retinopathy market in 2015. Diabetic retinopathy drug market in the region is expected to escalate and get sparked by huge government spending on healthcare industry in coming 5-6 years.

Europe is the second largest diabetic retinopathy drug market behind North America. The market in the region is anticipated to propagate by increasing number of obese people, who are more prone to diabetes, in some of the major European countries including the U.K., Germany, Spain, France, Italy and Spain. Asia-Pacific diabetic retinopathy drug market is believed to have the highest growth over the covered forecast period. Rapid expansion of diabetic population, increasing per capita income and major investments in health infrastructure are some of the key factors which are expected to propel the diabetic retinopathy drug market in countries such as India and China over next 4-5 years.

Japan diabetic retinopathy drug market is also anticipated to witness a burgeoned expansion fuelled by rapid growth of geriatric population in the country.

Key Players

Global diabetic retinopathy market is very competitive and includes some of the top players such as Roche, Moore Drug Company, Regeneron Pharmaceuticals Inc., Bayer Healthcare, ThromboGenics, Actavis PLC, Actavis PLC, Sirnaomics Incorporation, Parexel International Corp., etc.

Things to know


    • "This is an ongoing research and would be delivered in next 15-20 days."
    • Pre-Book now and get receive 10% discount.



    Direct access to analyst to help you understand the market in a better way to handle your critical question


    Citing your business specific requirement our consultant would assist you ensuring targeted goal is achieved


    Get 10% free customization


    Great focus on accuracy and quality of the research

Request for Toc

Call us

(U.S.) - +1 646 586 9123
(Canada) - +1 437 889 3230
(U.K.) - +44 203 608 5919
(India) - + 91 120 660 5495


Delivery Center

Ansal Corporate Park, Plot no 7A/1,
Tower A1,
Sector 142 Noida., 201301 India

US Office

77 Water Street 8th Floor,
New York, New York, 10005
Phone : +1 646 586 9123

Canada (Toronto)

Phone : +1 437 889 3230

UK Office (London)

Phone : +44 203 608 5919

Subscribe To Our Newsletters

Copyright © 2018 Research Nester. All rights reserved